Literature DB >> 8213241

Prolonged delirium tremens requiring massive doses of medication.

K M Wolf1, A F Shaughnessy, D B Middleton.   

Abstract

Delirium tremens might last for weeks and treatment requires massive benzodiazepine doses, yet it is possible to manage patients with this condition successfully. In this case of delirium tremens, standard agents at the usual recommended doses were not sufficient to achieve control of confusion and agitation or to stabilize neurologic and cardiovascular parameters. The patient required extraordinarily high doses of central nervous system depressants for an extended period. Midazolam, a short-acting benzodiazepine, was used but was associated with metabolic acidosis and was extremely expensive. Although high-dose midazolam should probably be avoided, extremely high dose benzodiazepine use for an extended period might be necessary in some cases. In this circumstance we advise diazepam because of its low cost and relative safety. The tendencies to withhold large doses for fear of side effects or to give up in cases requiring prolonged intensive support must be resisted to minimize the mortality from this severe illness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8213241

Source DB:  PubMed          Journal:  J Am Board Fam Pract        ISSN: 0893-8652


  3 in total

Review 1.  Identification and management of alcohol withdrawal syndrome.

Authors:  Antonio Mirijello; Cristina D'Angelo; Anna Ferrulli; Gabriele Vassallo; Mariangela Antonelli; Fabio Caputo; Lorenzo Leggio; Antonio Gasbarrini; Giovanni Addolorato
Journal:  Drugs       Date:  2015-03       Impact factor: 9.546

2.  Use of propofol as adjuvant therapy in refractory delirium tremens.

Authors:  Rajiv Mahajan; Rakendra Singh; Pir Dutta Bansal; Ranju Bala
Journal:  Ind Psychiatry J       Date:  2010-01

3.  Adjunctive Use of Ketamine for Benzodiazepine-Resistant Severe Alcohol Withdrawal: a Retrospective Evaluation.

Authors:  Poorvi Shah; Marc McDowell; Reika Ebisu; Tabassum Hanif; Theodore Toerne
Journal:  J Med Toxicol       Date:  2018-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.